Ion Beam Applications (IBA) and CMS reported that the St. Louis-based CMS has joined the Louvain-la-Neuve, Belgium-based IBA’s global particle therapy collaboration program at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Los Angeles.
The aim of the collaboration program is to offer integrated, open and comprehensive cancer treatment solutions to the particle therapy market. The program was initiated by IBA and Elekta earlier this week at ASTRO.
Under terms of the agreement, CMS will provide particle therapy solution packages to meet specific clinical requirements. This will add to the IBA offering an array of CMS products and solutions including XiO, a comprehensive treatment planning platform for photon, electron and proton planning, the Focal line of distributed planning workstations, and the CMS Direct suite of planning infrastructure and workflow management solutions.
"We are delighted to formalize our relationship with IBA and combine our best-of-breed products and capabilities to deliver a fully-integrated solution to the particle therapy market,” said Andrew Cowen, president and CEO of CMS.
“Our two companies share a common vision of product excellence in the particle therapy arena and a shared commitment to the clinicians who utilize our products and the patients who are treated with our solutions. CMS and IBA have collaborated successfully at several prominent proton treatment facilities including the FH Burr Proton Therapy Center at Massachusetts General Hospital and the Midwest Proton Radiotherapy Institute, and most recently at the first ProCure Treatment Center in Oklahoma City,” he said.